May 2016, Vol. 5, No. 4

← Back to Issue

Serving All on the Oncology Care Team


Letter to Our Readers

Dear Colleague,

Serving All on the Oncology Care TeamOver the past decade, we’ve experienced tremendous changes in the way we care for and treat patients with cancer. From research targets to available treatments; from management strategies to the very makeup of the multidisciplinary team. The publishers of Personalized Medicine in Oncology (PMO) recognize that to provide the best care to our patients, it takes a village. As a result, the oncology care team has evolved to include growing roles for physicians, nurses, pathologists, nurse and patient navigators, and, of course, the patient. To best support the efforts of those on the team, our publishers have multiple journals designed for members of the care team. Most recently, the publishers of PMO and the Journal of Oncology Navigation & Survivorship launched a patient magazine called CONQUER: the patient voice. This magazine was created in the hope of providing valuable information to patients, family, friends, and caregivers. We are delighted that CONQUER has celebrated its 1-year anniversary and hope it has proved valuable to your patients. We encourage you to pass the word along to your patients that this resource is available to them by visiting They can also complete the postcard on the cover and mail it to begin receiving future issues to their home address.

Within this issue of PMO, we feature an interview with the Editor in Chief of our sister publication, Journal of Oncology Navigation & Survivorship, Lillie D. Shockney, RN, BS, MAS, Johns Hopkins University, about the incorporation of the oncology nurse navigator into our cancer care teams.

We also feature an article from Drs Najjar and Kirkwood about the state of personalized medicine in melanoma as well as an insightful summary of research on perspectives of personalized medicine from Drs Miller, Garfield, and Woodman.

As always, we are proud to present The Last Word from Dr Edward Abrahams of the Personalized Medicine Coalition. In this installment, Dr Abrahams writes about Vice President Biden’s Moonshot initiative.

Thank you for your loyal readership. We value your participation; please contact us with your intriguing case studies, article ideas, and feedback at


Coeditor in Chief
Personalized Medicine in Oncology

Please visit today.

National Comprehensive Cancer Network - May 11, 2016

Test for EGFR Mutation in All Patients with NSCLC
Matching Treatment to Molecular Alteration Yields Best Outcomes

Tyrosine kinase inhibitors (TKIs) are the mainstay of treatment for patients with EGFR mutation–positive non–small cell lung cancer (NSCLC), according to the most recent guideline on management of NSCLC issued by the National Comprehensive Cancer Network (NCCN). Version 4.2016 of the guideline recommends EGFR testing as part of broader molecular [ Read More ]

National Comprehensive Cancer Network - May 11, 2016

Immunotherapy Takes Center Stage in NCCN Advanced Melanoma Guideline

The revised guideline (Version 2.2016) for the management of advanced melanoma, released by the National Comprehensive Cancer Network (NCCN), shows increasing appreciation for the use of immune checkpoint inhibitors and targeted agents, as more data establish these drug classes as having superior efficacy to traditional chemotherapy. “We’ve seen the approval [ Read More ]